Nicola Maruotti1, Francesco Paolo Cantatore. 1. Rheumatology Clinic "Mario Carrozzo", Department of Medical and Surgical Sciences, University of Foggia Medical School, "D'Avanzo" Hospital, Viale degli Aviatori 1, 71100, Foggia, Italy.
Abstract
PURPOSE: In this review, we focus on the clinical and radiological aspects related to the biological therapy of ankylosing spondylitis (AS), axial spondyloarthritis (SpA) and psoriatic arthritis (PsA). METHODS: A review was carried out in the main medical databases to evaluate the available literature. RESULTS: Even if there is emerging interest for the role of biological agents other than tumour necrosis factor (TNF)-α inhibitors in spondyloarthritis, anti-TNF-α treatment is currently the only effective therapy for patients in whom conventional therapy with non-steroideal anti-inflammatory drugs (NSAIDs) has failed. Nevertheless, the potential impact of earlier treatment and the best drugs or combinations of drugs for preventing radiographic progression in SpA are yet to be determined. CONCLUSIONS: Anti-TNF-α treatment is currently used with efficacy in the greater part of patients with SpA. In these patients, availability of biological treatment is limited on the bases of potential toxicity and cost. On the basis of clinical trials, biologics other than TNF-α inhibitors can currently not be recommended for the treatment of SpA.
PURPOSE: In this review, we focus on the clinical and radiological aspects related to the biological therapy of ankylosing spondylitis (AS), axial spondyloarthritis (SpA) and psoriatic arthritis (PsA). METHODS: A review was carried out in the main medical databases to evaluate the available literature. RESULTS: Even if there is emerging interest for the role of biological agents other than tumour necrosis factor (TNF)-α inhibitors in spondyloarthritis, anti-TNF-α treatment is currently the only effective therapy for patients in whom conventional therapy with non-steroideal anti-inflammatory drugs (NSAIDs) has failed. Nevertheless, the potential impact of earlier treatment and the best drugs or combinations of drugs for preventing radiographic progression in SpA are yet to be determined. CONCLUSIONS: Anti-TNF-α treatment is currently used with efficacy in the greater part of patients with SpA. In these patients, availability of biological treatment is limited on the bases of potential toxicity and cost. On the basis of clinical trials, biologics other than TNF-α inhibitors can currently not be recommended for the treatment of SpA.
Authors: Georg Schett; Jurgen Wollenhaupt; Kim Papp; Rik Joos; Jude F Rodrigues; Adele R Vessey; ChiaChi Hu; Randall Stevens; Kurt L de Vlam Journal: Arthritis Rheum Date: 2012-10
Authors: Daniel Wendling; Maxime Dougados; Francis Berenbaum; Olivier Brocq; Thierry Schaeverbeke; Bernard Mazieres; Christian Marcelli; Jean-Marie Leparc; Philippe Bertin; Michèle Robin; Jean Sibilia; Pierre Lafforgue; Clément Prati; Bernard Combe; Jacques-Eric Gottenberg Journal: J Rheumatol Date: 2012-08-15 Impact factor: 4.666
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler Journal: Arthritis Rheum Date: 2013-10
Authors: John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji Journal: Arthritis Rheum Date: 2003-11
Authors: Fernando Kemta Lekpa; Cécile Poulain; Daniel Wendling; Martin Soubrier; Michel De Bandt; Jean Marie Berthelot; Philippe Gaudin; Eric Toussirot; Philippe Goupille; Thao Pham; Jérémie Sellam; Rémy Bruckert; Muriel Paul; Valérie Farrenq; Pascal Claudepierre Journal: Arthritis Res Ther Date: 2012-03-09 Impact factor: 5.156
Authors: M Fabris; L Quartuccio; C Fabro; S Sacco; S Lombardi; R Ramonda; D Biasi; D Punzi; S Adami; I Olivieri; F Curcio; S De Vita Journal: Pharmacogenomics J Date: 2015-07-07 Impact factor: 3.550